Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2663 results

Media Release / Sep 27, 2015
Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET
In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
In The News / Jun 16, 2021
Novartis CEO outlines how to improve pandemic preparedness, warns another one is bound to happen
Novartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.
Pulse Update / Sep 02, 2021
Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
Pulse Update / May 25, 2021
Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes
Pulse Update / Jul 27, 2021
Novartis receives FDA Orphan Drug Designation for NIS793 in pancreatic cancer
Pulse Update / Aug 25, 2021
FDA accelerates review of Novartis STAMP inhibitor asciminib (ABL001) for patients with chronic myeloid leukemia (CML)
Pulse Update / Jul 06, 2021
Novartis announces Complete Response Resubmission for inclisiran New Drug Application
Pulse Update / Sep 03, 2021
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
Pulse Update / Jun 10, 2021
Novartis Entresto® indicated for treatment of hypertension in China
Story / Jul 31, 2014
New drugs could offer hope for malaria patients
Access to Healthcare
In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.